RT Journal Article
SR Electronic
T1 Three-Day Topotecan Schedule in Heavily Pretreated Recurrent Ovarian Cancer Patients
JF International Journal of Gynecologic Cancer
JO Int J Gynecol Cancer
FD BMJ Publishing Group Ltd
SP 455
OP 459
DO 10.1111/IGC.0b013e3181a1a7d2
VO 19
IS 3
A1 Marco Calcagno
A1 Filippo Bellati
A1 Innocenza Palaia
A1 Francesco Plotti
A1 Stefano Basile
A1 Maria Pastore
A1 Milena Sansone
A1 Cristiana Arrivi
A1 Roberto Angioli
A1 Pierluigi Benedetti Panici
YR 2009
UL http://ijgc.bmj.com/content/19/3/455.abstract
AB Objective: To evaluate the clinical benefit of a 3-day topotecan schedule in heavily pretreated recurrent ovarian cancer patients scheduled for palliative treatment.Methods: Eligibility criteria were 2 or more prior chemotherapy regimens, Eastern Cooperative Oncology Group performance status of 2 or less; adequate organ function, assessable disease by serum CA-125 measurement before each cycle; and 1 or more cycle of topotecan (1.5 mg/m2 per day) on 3 consecutive days of a 28-day treatment cycle. Toxicity was graded according to the National Cancer Institute Common Toxicity Criteria version 3. Tumor response, stable disease, and progression were evaluated on the basis of CA-125 levels.Results: A total of 68 patients were considered eligible for the study. Median age was 58 years (range, 40-77 years), and the median number of prior chemotherapy regimens was 2 (range, 2-6). A total of 272 cycles of topotecan were administered, with a median of 4 cycles per patient (range, 1-8). No treatment delays or dose reduction was recorded. Major toxicities were grade 3/4 (18%) neutropenia, neutropenic fever (6%), grade 4 thrombocytopenia (3%), requirements for blood (5%), and platelet transfusions (3%). Thirty-five (54%) of the 64 evaluable patients showed a clinical benefit. Of these, 11 patients (17%) had a partial response, and 24 (37%) had stable disease with a median time to progression of 7.5 months (range, 6-10 months) and 4 months (range, 2-6 months), respectively.Conclusion: More than half of heavily pretreated ovarian cancer patients may benefit from 3-day topotecan.